Heart Failure & Renal Protection

Adding Spironolactone to Dapagliflozin in HFmrEF/HFpEF: A Modest NT-proBNP Signal (SOGALDI-PEF)

In the SOGALDI-PEF crossover trial, adding spironolactone to dapagliflozin produced a modest 11% NT-proBNP reduction in HFmrEF/HFpEF, offset by eGFR decline and higher potassium. PICO summary and expert commentary.

Do SGLT2 Inhibitors Reduce Myocardial Fibrosis in Diabetic HFpEF?

A double-blind randomised trial of dapagliflozin versus placebo for myocardial fibrosis on cardiac MRI in 100 patients with type 2 diabetes and HFpEF. PICO summary and expert commentary.

Does Semaglutide Improve Symptoms and Weight Loss in Both Men and Women With Obesity-Related HFpEF?

Health Coaching and eGFR in Early Diabetic Kidney Disease: A Small RCT

A 92-patient randomized trial in Taiwan tested whether 6-month health coaching improves eGFR in type 2 diabetes with early-stage CKD. PICO summary and expert commentary.

Plasma Proteome Signatures of ASK1 Inhibition by Selonsertib in Diabetic Kidney Disease

An exploratory plasma proteomic analysis of the Phase 2b MOSAIC trial maps selonsertib activity to fibrosis, inflammation and oxidative-stress pathways in diabetic kidney disease, with PICO summary and expert commentary.

Finerenone in Chinese Patients with Type 2 Diabetes and CKD: A FIGARO-DKD Subgroup Analysis

A prespecified FIGARO-DKD subgroup analysis of 325 Chinese adults with type 2 diabetes and CKD found a significant reduction in the secondary kidney outcome with finerenone but no significant cardiovascular benefit. PICO summary and expert commentary.

Empagliflozin and Cardiac Reserve in Diabetic HFpEF: A Small Open-Label Mechanistic RCT

A single-centre, open-label randomised trial of empagliflozin 10 mg in 70 patients with type 2 diabetes and HFpEF found improved 6-minute walk distance and diastolic reserve markers. PICO summary and expert commentary.

DAPA ACT HF-TIMI 68: Rationale and Design of In-Hospital Dapagliflozin in Acute Heart Failure

Design paper for the DAPA ACT HF-TIMI 68 trial testing in-hospital dapagliflozin versus placebo in 2,401 patients with acute heart failure; no efficacy results are reported. PICO summary and expert commentary.

Does Empagliflozin Boost Red Blood Cell Production in Heart Failure?

A biomarker substudy of the EMPEROR program shows empagliflozin activates the erythropoietin-erythroferrone-hepcidin axis and raises haemoglobin in heart failure. PICO summary and expert commentary.

Ipragliflozin and Diastolic Function in Diabetic CKD: A Null Primary Endpoint With Exploratory LVEF and BMI Signals (PROCEED Sub-Analysis)

A post-hoc sub-analysis of the open-label PROCEED RCT found ipragliflozin did not improve LV diastolic function overall, with only exploratory subgroup signals. PICO summary and expert commentary.